Citadel Advisors’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
Citadel Advisors's DFTX Position: Q3 2026 in Review
Citadel Advisors sold out of Definium Therapeutics (DFTX) in Q3 2026, closing a stake of 1,688,587 shares — an estimated $71.2M sold.
Citadel Advisors first reported a position in DFTX in Q2 2021 and held it in 20 quarters. The position peaked at $79.4M in Q2 2026. 354 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.
- Citadel Advisors reported no remaining Definium Therapeutics position as of Q3 2026 after selling out during the quarter.
- Citadel Advisors sold 1,688,587 Definium Therapeutics shares in Q3 2026, an estimated $71.2M.
- Citadel Advisors first reported a position in Definium Therapeutics in Q2 2021 and held it in 20 quarters.
- Citadel Advisors's Definium Therapeutics position peaked at $79.4M in Q2 2026.
- 354 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.